title: Intravenous chemotherapy, early debulking surgery, and consolidation intraperitoneal chemotherapy in advanced ovarian carcinoma.
abstract: OBJECTIVE
  The efficacy of a cisplatin-anthracycline combination, early debulking surgery, and intraperitoneal chemotherapy has been demonstrated through separate studies. We evaluated a multimodal treatment strategy integrating these therapeutic options.
  
  
  METHODS
  Women with stage III or IV ovarian carcinoma received six cycles of cisplatin/epirubicin alternating with leucovorin and 5-fluorouracil. Patients with a residual disease (RD) measuring more than 2 cm after the initial laparotomy underwent an early debulking surgery after the first three cycles of chemotherapy. A second-look laparotomy (SLL) was performed after six cycles of intravenous chemotherapy. Intraperitoneal chemotherapy with cisplatin, VP16, and mitoxantrone was then administered in patients with no or RD < 2 cm after SLL.
  
  
  RESULTS
  A total of 87 patients were included. After initial laparotomy, 11 patients (12%) had no macroscopic residual disease, 38 (44%) had a RD < or =2 cm, and 38 (44%) had a RD > 2 cm. After early debulking surgery, an additional 18 patients (21%) had a RD < 2 cm. Seventy-five patients were evaluable for response to intravenous chemotherapy: the overall response rate was 80%, and 30 patients achieved a pathological complete response (40%). Eight percent of the patients had stable disease and 12% had a progression. Sixty-eight patients received intraperitoneal chemotherapy after second-look laparotomy. With a 72-month median follow-up, median overall survival and progression-free survival were, respectively, 37 and 19 months. Five-year survival was 41%.
  
  
  CONCLUSIONS
  The prognosis of patients with advanced ovarian carcinoma may be improved by a sequential treatment strategy including intravenous chemotherapy, early debulking surgery, and intraperitoneal chemotherapy.
authors.affiliation: Service d'Oncologie Médicale, Hôpital Saint Antoine, Paris, France. christophe.tournigand@sat.ap-hop-paris.fr
authors.forename: C
authors.initials: C
authors.lastname: Tournigand
authors.forename: C
authors.initials: C
authors.lastname: Louvet
authors.forename: J L
authors.initials: JL
authors.lastname: Molitor
authors.forename: N
authors.initials: N
authors.lastname: Dehni
authors.forename: V
authors.initials: V
authors.lastname: Lejeune
authors.forename: A
authors.initials: A
authors.lastname: Sezeur
authors.forename: A
authors.initials: A
authors.lastname: Pigne
authors.forename: L
authors.initials: L
authors.lastname: Marpeau
authors.forename: J
authors.initials: J
authors.lastname: Cady
authors.forename: A
authors.initials: A
authors.lastname: de Gramont
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D018572:Disease-Free Survival; D015251:Epirubicin / Q000008:administration & dosage / Q000009:adverse effects; D004847:Epithelial Cells / Q000473:pathology; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D007262:Infusions, Intravenous; D007263:Infusions, Parenteral; D007813:Laparotomy; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage / Q000009:adverse effects; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000601:surgery*; D011182:Postoperative Care; D024162:Second-Look Surgery
chemical_list: D015251:Epirubicin; D005047:Etoposide; D008942:Mitoxantrone; D002945:Cisplatin; D005472:Fluorouracil